These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 34009823)

  • 1. Re. A Cautionary Note on Extended Kaplan-Meier Curves for Time-varying Covariates.
    Steen J
    Epidemiology; 2021 Jul; 32(4):e13-e14. PubMed ID: 34009823
    [No Abstract]   [Full Text] [Related]  

  • 2. A Cautionary Note on Extended Kaplan-Meier Curves for Time-varying Covariates.
    Sjölander A
    Epidemiology; 2020 Jul; 31(4):517-522. PubMed ID: 32282405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cautionary note regarding the use of CIs obtained from Kaplan-Meier survival curves.
    Carter RE; Huang P
    J Clin Oncol; 2009 Jan; 27(2):174-5. PubMed ID: 19047307
    [No Abstract]   [Full Text] [Related]  

  • 4. Doubly robust estimator of risk in the presence of censoring dependent on time-varying covariates: application to a primary prevention trial for coronary events with pravastatin.
    Kawahara T; Shinozaki T; Matsuyama Y
    BMC Med Res Methodol; 2020 Jul; 20(1):204. PubMed ID: 32736528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis.
    Lueza B; Rotolo F; Bonastre J; Pignon JP; Michiels S
    BMC Med Res Methodol; 2016 Mar; 16():37. PubMed ID: 27025706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac resynchronization therapy in patients with class I-II heart failure and a wide QRS: a cautionary note.
    Tang WH; Francis GS
    Circulation; 2011 Jan; 123(2):203-8. PubMed ID: 21242506
    [No Abstract]   [Full Text] [Related]  

  • 7. A comparison of the Cox model to the Fine-Gray model for survival analyses of re-fracture rates.
    Nolan EK; Chen HY
    Arch Osteoporos; 2020 Jun; 15(1):86. PubMed ID: 32519193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Painting by number--Survival curves and Kaplan-Meier method].
    Schindler B; Briel M; Günther J
    Med Monatsschr Pharm; 2015 May; 38(5):186-91. PubMed ID: 26364408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kaplan-Meier curves for survivor causal effects with time-to-event outcomes.
    Chiba Y
    Clin Trials; 2013 Aug; 10(4):515-21. PubMed ID: 23610455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Competing risk bias was common in Kaplan-Meier risk estimates published in prominent medical journals.
    van Walraven C; McAlister FA
    J Clin Epidemiol; 2016 Jan; 69():170-3.e8. PubMed ID: 26232083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bias-adjusted Kaplan-Meier survival curves for marginal treatment effect in observational studies.
    Wang X; Bai F; Pang H; George SL
    J Biopharm Stat; 2019; 29(4):592-605. PubMed ID: 31286838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kaplan-Meier survival curves.
    Hess AS; Hess JR
    Transfusion; 2020 Apr; 60(4):670-672. PubMed ID: 32077507
    [No Abstract]   [Full Text] [Related]  

  • 13. Censored patients in Kaplan-Meier plots of cancer drugs: An empirical analysis of data sharing.
    Rosen K; Prasad V; Chen EY
    Eur J Cancer; 2020 Dec; 141():152-161. PubMed ID: 33160265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival analysis (Kaplan-Meier curves): a method to predict the future.
    Lira RPC; Antunes-Foschini R; Rocha EM
    Arq Bras Oftalmol; 2020; 83(2):V-VII. PubMed ID: 32159589
    [No Abstract]   [Full Text] [Related]  

  • 15. Proposals on Kaplan-Meier plots in medical research and a survey of stakeholder views: KMunicate.
    Morris TP; Jarvis CI; Cragg W; Phillips PPJ; Choodari-Oskooei B; Sydes MR
    BMJ Open; 2019 Sep; 9(9):e030215. PubMed ID: 31575572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating hazard ratios from published Kaplan-Meier survival curves: A methods validation study.
    Saluja R; Cheng S; Delos Santos KA; Chan KKW
    Res Synth Methods; 2019 Sep; 10(3):465-475. PubMed ID: 31134735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk-difference curves can be used to communicate time-dependent effects of adjuvant therapies for early stage cancer.
    Coory M; Lamb KE; Sorich M
    J Clin Epidemiol; 2014 Sep; 67(9):966-72. PubMed ID: 24794698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Daily Struggle to Improve Kaplan-Meier Curves-Doctors on the Swing.
    Badinella Martini M
    JAMA Oncol; 2020 Jan; 6(1):27-28. PubMed ID: 31600362
    [No Abstract]   [Full Text] [Related]  

  • 19. Optimizing the presentation of bleeding and thrombosis data: Responding to censored data using Kaplan-Meier curves.
    Bouck EG; Zunica ER; Nieman MT
    Thromb Res; 2017 Oct; 158():154-156. PubMed ID: 28926800
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparing Kaplan-Meier curves with the probability of agreement.
    Stevens NT; Lu L
    Stat Med; 2020 Dec; 39(30):4621-4635. PubMed ID: 32969528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.